Directed Evolution: Bringing New Chemistry to Life by Arnold, Frances H.
German Edition: DOI: 10.1002/ange.201708408Biocatalysis
International Edition: DOI: 10.1002/anie.201708408
Directed Evolution: Bringing New Chemistry to Life
Frances H. Arnold*
biocatalysis · enzymes · heme proteins ·
protein engineering · synthetic methods
Survival of the Fittest
In this competitive age, when new industries sprout and
decay in the span of a decade, we should reflect on how
a company survives to celebrate its 350th anniversary. A
prerequisite for survival in business is the ability to adapt to
changing environments and tastes, and to sense, anticipate,
and meet needs faster and better than the competition. This
requires constant innovation as well as focused attention to
execution. A company that continues to provide meaningful
and profitable solutions to human problems has a chance to
survive, even thrive, in a rapidly changing and highly
competitive world.
Biology has a brilliant algorithm for solving the problem
of survival over time: evolution. Those who adapt and
(re)produce outcompete the less agile and less fertile. Over
the last 30 years—which seems a long time but is less than
one-tenth the time Merck KGaA, Darmstadt, Germany has
been in business—I have tried to adapt biologyQs mechanisms
for innovation and optimization to solving problems in
chemistry and engineering. It turns out that evolution is
a powerful forward-engineering process, whose widespread
adoption in enzyme engineering and synthetic biology has
been made possible through advances in molecular biology
and high-throughput screening.
Expanding Nature’s Catalytic Repertoire for
a Sustainable Chemical Industry
Nature, the best chemist of all time, solves the difficult
problem of being alive and enduring for billions of years,
under an astonishing range of conditions. Most of the
marvelous chemistry that makes life possible is the work of
natureQs macromolecular protein catalysts, the enzymes. By
using enzymes, nature can extract materials and energy from
the environment and convert them into self-replicating, self-
repairing, mobile, adaptable, and sometimes even thinking
biochemical systems. These systems are good models for
a sustainable chemical industry that uses renewable resources
and recycles a good fraction of its products. And biology is not
just a model from which to draw inspiration: living organisms
or their components can be efficient production platforms. In
fact, I predict that DNA-programmable microorganisms will
be producing many of our chemicals in the not-so-distant
future.
That most chemicals are made using synthetic processes
starting from petroleum-based feedstocks reflects the re-
markable creativity of synthetic chemists in developing
reaction schemes and catalysts that nature never discovered.
Synthetic chemistry has given us an explosion of products,
which feed, clothe, house, entertain, and cure us. Synthetic
chemistry, however, struggles to match the efficiency and
selectivity that biology achieves with enzymes. In many cases,
synthetic processes rely on precious metals, toxic reagents and
solvents, and extreme conditions, and they generate substan-
tial amounts of unwanted byproducts. DNA-programmable
chemical synthesis using enzymes promises to improve on
synthetic chemistry, particularly if we are able to expand
biologyQs catalytic repertoire to include some of the most
synthetically useful reactions, under physiological conditions
and with earth-abundant resources. Such clean, green chemis-
try might sound like pie in the sky, but enzymes already show
how a protein can orient substrates for reaction, exclude
water from an active site, activate a metal or simple organic
cofactor, or suppress competing reactions to draw out new
and admirable synthetic capabilities. Synthetic chemists have
been drawing inspiration from biology for decades, and now is
the time for protein engineers to use inspiration from
synthetic chemistry to generate new enzymes that will
improve on and replace synthetic catalysts and reaction
pathways.[1]
Unfortunately, our understanding of the link between
sequence and function lags well behind our desire for new
[*] Prof. F. H. Arnold
Division of Chemistry and Chemical Engineering
California Institute of Technology 210-41
1200 E. California Blvd., Pasadena, CA 91125 (USA)
E-mail: frances@cheme.caltech.edu
Homepage: http://fhalab.caltech.edu
The ORCID identification number for the author of this article can be
found under https://doi.org/10.1002/anie.201708408.
T 2017 The Authors. Published by Wiley-VCH Verlag GmbH & Co.
KGaA. This is an open access article under the terms of the Creative
Commons Attribution Non-Commercial License, which permits use,
distribution and reproduction in any medium, provided the original
work is properly cited, and is not used for commercial purposes.
This article is part of the Special Issue to commemorate the 350th
anniversary of Merck KGaA, Darmstadt, Germany. More articles can
be found at http://doi.wiley.com/10.1002/anie.v57.16.
Angewandte
ChemieEssays
4143Angew. Chem. Int. Ed. 2018, 57, 4143 – 4148 T 2018 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
enzymes. Given that our ability to predict protein sequences,
or even just changes to a sequence, which reliably give rise to
whole new, finely tuned catalytic activities is rudimentary at
best, creating new enzymes capable of improving on current
synthetic processes is a pretty tall order. We also dream of
going beyond known chemistry to create enzymes that
catalyze reactions or make products that are simply not
possible with any known method, synthetic or otherwise.
Requiring that these new enzymes assemble and function in
cells, where they can be made at low cost and incorporated
into synthetic metabolic pathways to generate a broader array
of products, represents an even greater set of engineering
constraints and challenges.
NatureQs enzymes are the products of evolution, not
design. By using generations of mutation and selection for
fitness advantages, evolution allows organisms to continu-
ously update and optimize their enzyme repertoires. New
enzymes even appear in real time in response to challenges
(e.g. the need to resist antibiotics or pesticides) or oppor-
tunities (e.g. the chance to occupy a new food niche by
degrading recently introduced, manmade substances). I argue
that the process that gave rise to all the remarkable biological
catalysts in nature should be able to produce yet more. In the
laboratory. Quickly. Advances in molecular biology over the
past few decades—the ability to write, cut, and paste DNA
and to have that DNA read and translated into proteins in
recombinant organisms—have given us the ability to breed
enzymes much like we breed sheep or sake yeast. We can
direct the evolution of enzymes in the laboratory by requiring
them to perform in ways that may not be useful to a bacterium
but are useful to us. Directed evolution achieves these
desirable functional outcomes while circumventing our deep
ignorance of how sequence encodes them.
Directed evolution mimics evolution by artificial selec-
tion, and is accelerated in the laboratory setting by focusing
on individual genes expressed in fast-growing microorgan-
isms. We start with existing proteins (sourced from nature or
engineered), introduce mutations, and then screen for the
progeny proteins with enhanced activity (or another desirable
trait). We use the improved enzymes as parents for the next
round of mutation and screening, recombining beneficial
mutations as needed, and continuing until we reach the target
level of performance.
Engineering enzymes in the 1980s and 1990s, I learned the
hard way that there was no reliable method to predict
performance-enhancing mutations. Turning instead to ran-
dom mutagenesis and screening, I quickly realized that such
mutations were easy to find and accumulate with the right
evolutionary optimization strategy. My students and I ob-
served that proteins, the products of evolution, are themselves
readily evolvable. Properties we and others targeted in the
early days of directed evolution (the mid-1990s) included
recovering activity in unusual environments (e.g. organic
solvents), improving activity on non-native substrates, en-
hancing thermostability, and changing enantioselectivity. We
learned the then-surprising fact that beneficial mutations
could be far from an active site, and often appeared on the
protein surface (which in those days was generally deemed
insensitive to mutation and functionally neutral). To this day,
no one can explain satisfactorily how such mutations exert
their effects, much less predict them.
Evolution of Novelty: Enzymes that Catalyze
Reactions Invented by Synthetic Chemists
Although we could enhance activity (and many other
properties) by accumulating beneficial mutations over gen-
erations of random mutagenesis and screening, evolving
a whole new catalytic activity seemed a much more difficult
problem. After all, evolution is not good for problems that
require multiple, simultaneous, low-probability events,[2] and
the active sites of enzymes are so beautifully and precisely
configured that it was hard to imagine how the stepwise
accumulation of beneficial mutations could create a new one.
EvolutionQs innovation mechanisms, however, are more
simple than they might appear: evolution works best when it
does not need to generate a whole new active site from
scratch. Instead, evolution can generate a new enzyme from
one that is “close”, that is, shares elements of mechanism or
machinery from which the new activity can be built. Nature
co-opts old machinery to do new jobs. And sometimes the
ability to do the new job is already there, at least at a low level.
The biological world is replete with proteins whose capabil-
ities extend well beyond what may be used at any given time.
Thus new enzymes are built from promiscuous or side
activities that become advantageous in a new biological
context, such as when a new food source becomes available.[3]
Thus a conservative process of accumulating beneficial
mutations can innovate because the innovation is already
there! The magnificent diversity of the biological world
provides the fuel for further innovations.
For directed evolution to be a reliable approach to
creating new enzymes, we the breeders of proteins must first
identify potential catalytic novelty in the form of starting
proteins which have at least low levels of a new activity. We
therefore look for activities that are known to synthetic
chemistry, but perhaps not explored in nature. Cytochrome
P450s, whose native functions include a variety of extremely
challenging transformations such as hydroxylation, epoxida-
tion, heteroatom oxidations, nitration and more, looked to me
like a promising place to start hunting for new activities.
Nature had already exploited this evolvable heme-protein
assembly and the various reactive intermediates in the
catalytic cycle to create all the natural P450 functions. We
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quickly discovered that many more new, non-natural func-
tions were possible. In the last few years we have engineered
P450s and other heme proteins to carry out a plethora of
reactions known to synthetic chemists, but not found in
biology.[4]
For example, olefin cyclopropanation by carbene transfer
is a reaction well known in the area of transition-metal
catalysis, but not known to be catalyzed by an enzyme. In
2012, inspired by much older reports of heme mimics
performing such reactions in organic solvents, we discovered
that heme proteins catalyze cyclopropanation when provided
with diazo carbene precursors and a suitable olefin, in water.[5]
This promiscuous activity is manifested when the protein
encounters the diazo reagent, forms the reactive carbene, and
then transfers it to the olefin. Our lab took advantage of this
inherent ability of a bacterial cytochrome P450 to evolve
a highly efficient enzyme for production of the chiral cis-
cyclopropane precursor to the antidepressant medication
levomilnacipran.[6] Our group and that of Rudi Fasan have
since pushed a variety of heme proteins to synthesize other
chiral cyclopropane pharmaceutical precursors, including one
used in the synthesis of ticagrelor, a medication used to
prevent the reoccurrence of heart attacks.[7] In our case, we
identified a truncated globin from Bacillus subtilis, which
catalyzes the reaction at low levels and also showed some
selectivity for producing the single, desired diastereomer of
the ticagrelor cyclopropane precursor from ethyl diazoacetate
and 3,4-difluorostyrene (Figure 1). Just a few generations of
directed evolution improved the activity and selectivity of the
enzyme so that, of the four possible stereoisomers, it produces
the ticagrelor cyclopropane almost exclusively. Because the
reaction proceeds in whole Escherichia coli cells which
express the evolved enzyme, producing the catalyst is as
simple as growing bacteria.
While we were investigating carbene-transfer reactions
catalyzed by heme proteins, we also looked into the possibility
of evolving enzymes for nitrene-transfer reactions. Inspired
by a hint in the literature from the 1980’s to attempt
intramolecular C@H amination, we were delighted to find
that a cytochrome “P411” exhibited a low level of promiscu-
ous activity with an aryl sulfonyl azide nitrene precursor, and
that activity could be improved by directed evolution.[8] We
purposefully engineered the P411 by replacing the completely
conserved cytochrome P450 cysteine ligand, which is bound to
the iron center, with serine, a ligand not found in any known
natural heme protein. This change shifts the characteristic
peak in the CO difference spectrum from l= 450 to 411 nm
and abolishes the native monooxygenase activity. It also
greatly promotes carbene-transfer and nitrene-transfer activ-
ities.
After demonstrating that the P411 derived from Bacillus
megaterium cytochrome P450 could be engineered for intra-
molecular C@H amination, and intermolecular aziridination
and sulfimidation activities unknown in biological systems,
our efforts culminated in cytochrome P411CHA, which cata-
lyzes intermolecular benzylic C@H amination.[9] Efficient and
highly enantioselective intermolecular amination of C(sp3)@
H bonds has long been a challenge in chemical catalysis.
Despite screening many different heme proteins and protein
variants, however, we never found one with the desired
activity until postdoctoral fellow Chris Prier discovered that
the P411 variant “P4”, evolved for an intermolecular sulfimi-
dation and rearrangement reaction, had acquired promiscu-
ous activity for benzylic C@H amination. Chris Prier and
doctoral student Kelly Zhang then directed the evolution of
P4 to create P411CHA, which exhibits hundreds of turnovers
for the amination of benzylic C@H bonds with excellent
enantioselectivities (> 99% ee).[9]
Free heme does not catalyze any of these nitrene-transfer
reactions, and small-molecule catalysts for direct C@H
amination rely heavily on precious metals which are not
sustainable. The protein, however, can impart this new
reactivity to earth-abundant iron in its porphyrin cofactor,
and it is evolvable. Evolution enabled P411CHA to promote
nitrenoid formation and transfer to a second substrate over
the competing nitrene reduction heavily favored in the parent
enzyme,[9] a property that would be extremely challenging, if
not impossible, to design. In fact, we think of these proteins as
chiral, self-assembling, DNA-encoded macromolecular tran-
sition-metal complexes whose steric and electronic properties
are readily tuned by directed evolution to achieve desired
activities and selectivities.
Recently we have been exploring enzymes that open yet
more chemical space for biocatalysis, including enzymes that
form chemical bonds unknown in biology. In the last year we
described heme enzymes that catalyze carbene insertion into
Si@H and B@H bonds, thus giving living systems their first
carbon–silicon[10] and carbon–boron[11] bond-forming activi-
ties. C@Si bonds are useful in medicinal chemistry, imaging
agents, elastomers, and a wide variety of consumer products,
but they have never been found in biological systems. Until
now, the only methods to create these bonds enantioselec-
tively involved multistep syntheses just to prepare chiral
reagents or chiral transition-metal complexes. The resulting
catalysts are often only poorly active, and an iron-based
catalyst had never been reported for this carbene-insertion
reaction. Upon screening a collection of heme proteins,
postdoctoral fellow Jennifer Kan and her team discovered
that a small (124 aa), highly stable cytochrome c from
Rhodothermus marinus (Rma cyt c) could catalyze the
reaction between ethyl 2-diazopropanoate and phenyldime-
thylsilane to form the chiral organosilicon product with high
enantioselectivity (Figure 2A). Directed evolution discov-
ered three mutations that enable the enzyme to form C@Si
bonds with up to 8200 total turnovers (based on Rma cyt c
concentration) and enantioselectivities with greater than
99% ee for a wide range of silicon-containing substrates.
Figure 1. A B. subtilis globin variant, engineered by directed evolution,
catalyzes the cyclopropanation of 3,4-difluorostyrene to make the
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Doctoral student Kai Chen used the engineered enzyme to
make 20 organosilicon products, most of which were obtained
as single enantiomers. The evolved enzyme also became
highly chemoselective for Si@H insertion using substrates
having other potentially reactive functional groups (alkene,
alkyne, N@H, O@H; Figure 2B).
We also asked whether an enzyme could catalyze carbene
insertion into B@H bonds. No C@B bonds are known in the
biological world, and the few natural products that include
boron in different forms are thought to incorporate boric acid,
available from the environment, non-enzymatically. Postdoc-
toral fellows Jennifer Kan and Xiongyi Huang proposed that
B@H insertion could be genetically encoded, thus giving living
cells the ability to make chiral organoborane products from
appropriate, biocompatible carbene precursors and borylat-
ing agents. Starting with the Rma cytochrome c, they evolved
a very efficient biocatalyst: bacteria expressing evolved Rma
cyt c provided access to 16 chiral organoboranes, which had
never been made previously, from borane-Lewis base com-
plexes and various carbene precursors.[11] Suitable for gram-
scale biosynthesis, the catalyst offered up to 15300 turnovers
(based on cytochrome c concentration), a 99:1 enantiomeric
ratio (e.r.), and 100% chemoselectivity (Figure 3). These
catalyst turnovers are more than 400 times greater than those
for known chiral catalysts for the same class of transforma-
tion. Furthermore, the enzymeQs enantio-preference could be
switched to make either product enantiomer. Fully genet-
ically encoded and functional for hours, these new enzymes
open a new world of silicon and boron chemistry in living
systems.
It has been fascinating to see that at least some of natureQs
vast catalogue of proteins can be evolved in the laboratory,
often with only a few mutations, to catalyze abiological
reactions (cyclopropanation, N@H insertion, S@H insertion,
amination, aziridination, and more). The new enzymes can
even create chemical bonds not known in biology (C@Si, C@
B). These new reactivities were made possible by 1) use of
reagents not found naturally (carbene and nitrene precur-
sors), 2) the promiscuous reactivities of proteins in the
presence of these synthetic reagents, 3) directed evolution
to enhance and tune the new activities, and 4) chemical
intuition and know-how to identify the right conditions and
reactions to test with the right enzymes.
Enzymes to Conquer New Chemistry
The next big challenge is to create enzymes for reactions
that neither biology nor synthetic chemistry has conquered.
As macromolecular catalysts, for example, enzymes can
stabilize transition states and promote reactions through
pathways that would be difficult, if not impossible, to access
with small-molecule catalysts because of competition with
other, lower-energy reaction pathways. In a powerful example
of how an enzyme active site can be engineered to promote
one reaction pathway over another, postdoctoral fellow
Stephan Hammer directed the evolution of an alkene anti-
Markovnikov oxygenase (aMOx), which catalyzes the con-
version of alkenes into the anti-Markovnikov carbonyl
compounds.[12] Intrigued by a report that the cytochrome
P450 from Labrenzia aggregata made some phenyacetalde-
hyde as a side product when it oxidized styrene to the epoxide,
Hammer looked more deeply and discovered that this
promiscuous reactivity did not involve epoxidation followed
by isomerization to the aldehyde, as had been proposed.[13]He
correctly surmised that it instead went through a competing,
stepwise mechanism involving radical/cation intermediates
and a 1,2-hydride migration (Figure 4A).[14] He then exploit-
ed this side activity to direct the evolution of by far the most
active, and the first enantioselective, direct aMOx catalyst.[12]
Using earth-abundant iron, dioxgen, and a recyclable cofactor
(NADPH), the laboratory-evolved P450 enzyme catalyzes
thousands of turnovers for anti-Markovnikov oxidation of
different substituted styrenes, including hindered substrates
such as internal and 1,1-disubstituted alkenes.
Figure 3. Production of chiral organoboranes by E. coli expressing
Rhodothermus marinus cytochrome c.[11] The bacterial catalyst uses
borane-Lewis base complexes and diazo reagents to construct boron-
containing carbon stereocenters efficiently and selectively in cells by
carbene B@H insertion. The bioconversion can be conducted readily
on gram scale, and the enantio-preference of borylation was switched
to give either enantiomer of the organoborane products.
Figure 2. A) Chiral Si@C bond formation catalyzed by a laboratory-
evolved variant of Rhodothermus marinus cytochrome c.[10] The three
amino acid residues that were mutated to increase this abiological
activity include the methionine axial ligand (M100). B) The enzyme
catalyzes formation of different organosilane products with high
enantiomeric excess from silane and diazo substrates.
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Remarkably, the aMOx enzyme reacts with 1,1-disubsti-
tuted alkenes and generates chiral centers by controlling the
enantioselectivity of the 1,2-hydride migration. It is difficult
to envision how this could be done outside of a macro-
molecular active site. The 12 mutations that confer this
impressive reactivity and control over substrate orientation
during the 1,2-hydride migration are distributed all over the
protein (Figure 4B). Their specific effects on the enzymeQs
structure and mechanism that led to this remarkable activity
are difficult to rationalize, much less predict.
Synthetic catalysts for anti-Markovnikov oxidation have
not been able to exploit the aMOx mechanism because of
competition from the highly favored concerted epoxidation
pathway. Instead, synthetic approaches use alternative strat-
egies that require precious metals and/or stoichiometric
oxidants such as iodosobenzene. Their very limited activities
cannot compete with the laboratory-evolved enzyme. No
catalytic, enantioselective method to convert prochiral al-
kenes into their chiral anti-Markovnikov carbonyl com-
pounds was known before this enzyme was engineered.
To enhance utility for production of fine chemicals, aMOx
can be coupled with other catalysts, such as an alcohol
dehydrogenase, to enable anti-Markovnikov redox hydration
of alkenes.[12] This coupled enzyme system yields valuable
chiral alcohols with high enantiomeric excess and has the
added benefit of recycling the NADPH cofactor. The anti-
Markovnikov alkene functionalization is an important step in
the production of many valuable chemicals, which are now in
principle approachable through the combination of an
evolved aMOx with other enzymes or chemical catalysts
(Figure 4C). Knowing that such a direct aMOx catalyst is
possible may inspire creation of even better enzymes or even
invention of smaller-molecule mimics.
Closing Thoughts
I have focused this essay on the efforts of my own group to
re-purpose heme proteins and to use them to demonstrate
that directed evolution (and a little design) can readily create
new genetically encoded enzyme catalysts for reactions first
invented by synthetic chemists and even for reactions which
have eluded synthetic approaches. The active sites of the new
enzymes can confer high activities and chemo-, regio-, and
enantioselectivies, as well as product selectivities, which are
difficult or impossible to achieve with small-molecule cata-
lysts. Furthermore, laboratory-evolved enzymes can stabilize
and direct the fates of highly reactive intermediates to
promote reactions that are disfavored without the precise
control of the enzyme. We hope that these demonstrations
will soon be accompanied by deeper insights into the
mechanisms of the new enzyme-catalyzed reactions gained
from ongoing structural, spectroscopic, and computational
studies.
Other excellent examples of directed evolution for non-
natural chemistry have been produced by other groups,
including designed enzymes and enzymes with artificial
cofactors, some of which are described in our recent review.[15]
The designed enzymes donQt yet have the sophistication of
natureQs products, and design struggles with the metals and
other cofactors that drive so much interesting chemistry. But
when that changes, directed evolution will be there to draw
out the new capabilities and fine-tune the designs, just as it
can do with the promiscuous activities of natural proteins.
With the power of evolution realized for engineering, we
now have a whole new way to look at the diverse products of
natural evolution. Instead of simply asking what enzymes do
in nature, we can now ask the question, “what CAN they do?”
It will turn out that they can do a lot more than we ever
imagined, especially when we use evolution to unleash their
latent potentials. What is clear is that evolution is an
innovation machine, and natureQs products are ready to be
let loose to take on new functions, under the discerning eye of
the breeder of molecules. A treasure trove of new enzymes is
just waiting to be discovered and used for chemistry that we
could only have dreamed of just a few years ago.
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